LHC Group, Inc.
LHC Group, Inc. (LHCG) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lhcg · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for LHC Group, Inc. (LHCG) measures how much investors pay for each dollar of the company's trailing earnings. LHCG's current PE ratio of 86.41x is calculated by dividing its stock price of $169.81 by its TTM earnings per share of $1.97. +67.3% elevated vs 5Y avg 51.6x
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2003 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%23.7x
MedianQ3 · 75%82.3x
Max
At 86.41x, LHCG's current P/E is higher than in 100% of its annual fiscal year readings over the past 19 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Care Facilities · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
LHC Group, Inc.You LHCG | $5.3B | 86.41x | +40.7% | $1.97 |
 Abcam plc ABCM | $5.5B | N/A | — | -$0.04 |
 Alpine Immune Sciences, Inc. ALPN | $4.5B | N/A | — | -$0.64 |
 Amedisys, Inc. AMED | $3.3B | 68.71x | +11.9% | $1.32 |
 Astrana Health, Inc. ASTH | $1.9B | 54.15x | -11.9% | $0.46 |
 IVERIC bio, Inc. ISEE | $5.5B | N/A | — | -$1.45 |
 Mirati Therapeutics, Inc. MRTX | $4.1B | N/A | — | -$13.18 |
Industry Average 2 peers with valid PE | — | 61.43x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | 82.28x | $1.97 | +173.9% | |
2021-12-31 FY2021 | 30.04x | $4.57 | -49.9% | |
2020-12-31 FY2020 | 59.96x | $3.56 | +33.5% | |
2019-12-31 FY2019 | 44.91x | $3.07 | +9.5% | |
2018-12-31 FY2018 | 41.01x | $2.29 | +89.4% | |
2017-12-31 FY2017 | 21.65x | $2.83 | -1.3% | |
2016-12-31 FY2016 | 21.94x | $2.08 | -10.0% | |
2015-12-31 FY2015 | 24.38x | $1.86 | -0.9% | |
2014-12-31 FY2014 | 24.60x | $1.27 | +34.1% | |
2013-12-31 FY2013 | 18.35x | $1.31 | +32.4% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for LHC Group, Inc. (LHCG) measures how much investors pay for each dollar of the company's trailing earnings. LHCG's current PE ratio of 86.41x is calculated by dividing its stock price of $169.81 by its TTM earnings per share of $1.97.
Frequently asked questions
LHCG pe ratio · 6 questionsLHCG's current PE ratio is 86.41x as of 2026-06-09, based on a stock price of $169.81 and TTM EPS of $1.97. Data sourced from Financial Modeling Prep via LHCG's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · LHC Group, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09